黑料网

Abstract

The field of minimal residual disease in most B-cell malignancies is critical. This is especially true for mantle cell lymphoma, a rare but aggressive subtype of non-Hodgkin’s lymphoma. A recent review of available minimal residual disease assessment methods has shown promising results in mantle cell lymphoma, specifically in the advancement of circulating tumour DNA-based liquid biopsy methods. While there are various minimal residual disease markers in mantle cell lymphoma, finding the best suitable marker remains a problem yet to be solved. Because minimal residual disease monitoring is not yet validated in clinical trials, seeing studies that include such an assessment has become valuable in determining if it can accurately aid in identifying future prognostics and outcomes of a chosen therapy method. By using next generation sequencing methods, liquid biopsy is able to utilize various sample types, like circulating tumour cells, cell-free DNA, circulating tumour DNA, and etc., from a drop of blood to assess the molecular landscape of the tumour in a non-invasive manner. More recent updates on the basic methods, available markers, and liquid biopsy assessments in mantle cell lymphoma are described in this mini-review.

Keywords: Non-Hodgkin lymphoma; Minimal Residual Disease (MRD); Mantle cell lymphoma; Lymphocytic leukaemia